FDA Approves Orilissa (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis

Article Link: FDA Approves Orilissa (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis

NORTH CHICAGO, Ill., July 24, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA)…

Source: FDA New Drug Approvals